What is Dekk-tec?
Dekk-tec, Inc. is a biotechnology firm established in 1983, dedicated to pioneering innovative treatments for cancer. The company's core focus lies in the development of novel drugs and devices, with lead therapeutic agents including DM-CHOC-PEN and hydroperoxy analogs. These agents are engineered to manage both cancer and pre-cancerous lesions. Dekk-tec strategically targets oncology markets, with a particular emphasis on CNS and metastatic stage solid tumors. The company possesses a robust track record in clinical development and has experience with regulatory submissions, having successfully licensed products to other biotech entities. Currently, Dekk-tec is advancing its lead agent through critical clinical trials.
How much funding has Dekk-tec raised?
Dekk-tec has raised a total of $13K across 1 funding round:
Debt
$13K
Debt (2021): $13K with participation from PPP
What's next for Dekk-tec?
With the recent injection of moderate growth capital, Dekk-tec is poised to further its strategic objectives in the competitive oncology landscape. The company's established history and focus on novel therapeutic agents suggest a trajectory aimed at advancing its lead candidates through further clinical development and potential commercialization. This funding will likely support expanded clinical trial operations, research and development initiatives, and potentially bolster regulatory affairs efforts as the company moves closer to market. The Series A/B growth stage context indicates a focus on scaling operations and solidifying its market position within the specialized field of cancer treatment.
See full Dekk-tec company page
